Waleed Fathy Ali Esmael

01/06/2024

https://onlinelibrary.wiley.com/doi/10.1111/cid.13324

Waleed Fathy Ali Esmael

31/03/2024

https://pubmed.ncbi.nlm.nih.gov/38556885/

Waleed Fathy Ali Esmael

01/06/2023

https://digitalcommons.aaru.edu.jo/fdj/vol9/iss1/5/

Waleed Fathy Ali Esmael

01/12/2022

https://digitalcommons.aaru.edu.jo/fdj/vol8/iss2/7/

Waleed Fathy Ali Esmael

01/10/2021

https://digitalcommons.aaru.edu.jo/cgi/viewcontent.cgi?article=1126&context=fdj

Waleed Fathy Ali Esmael

01/12/2016

https://www.sciencedirect.com/science/article/pii/S2314718016300337

Waleed Fathy Ali Esmael

01/01/2010

Abstract Objective. The purpose of this study was to assess the efficacy of Botulinum Toxin Type A (BTX-A) in the treatment of chronic recurrent temporomandibular joint dislocation. Study design. Subjects were 16 patients (6 male & 10 female) who suffered from bilateral chronic recurrent TMJ dislocation. Patients were randomized into two equal groups. Each patient in Group I received 100 U BTX-A as electromyographic guided injection into the lateral pterygoid muscles bilaterally via an intraoral approach (50 U each side). Each patient in Group II received 2 ml normal saline injected into the lateral pterygoid muscles bilaterally (1 ml each side). Patients were followed up for 6 months following the injection. Results. There was statistically significant decrease in mean mouth opening and pain score in Group I patients. Conclusion. BTX-A has proven to be safe and effective in the treatment of chronic recurrent Temporomandibular joint dislocation. Key words : • Temporomandibular Joint. • Recurrent Dislocation.